Mixed Mode Chromatography Resin Market Size Estimated to Reach US$ 743 Million at a CAGR of 15.7% by 2035

The mixed mode chromatography resins market is projected to reach a valuation of USD 172 million in 2025, and according to Fact.MR, it is expected to expand at a robust CAGR of 15.7%, hitting approximately USD 743 million by 2035.

These resins utilize multimodal ligands, allowing for protein binding through a combination of ionic interactions, hydrogen bonding, and hydrophobic forces. This multifaceted binding mechanism offers superior selectivity, resolution, and loading capacity compared to traditional single-mode chromatography systems. The year 2024 marked a pivotal phase for the industry, driven by increasing demand for advanced separation technologies, particularly in the pharmaceutical and biotechnology sectors. Innovations in resin chemistry and growing bioprocessing applications have elevated the importance of mixed mode chromatography in areas such as monoclonal antibody purification, vaccines, and gene therapies. The market is set to gain further momentum as regulatory expectations and efficiency standards continue to rise in bioseparation processes.

For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=7451

Country-Wise Analysis

The United States remains at the forefront of biopharmaceutical innovation, making it the most influential market for mixed mode chromatography resins. Its well-established R&D ecosystem, combined with the presence of leading biologics manufacturers, consistently drives demand for advanced purification technologies that support complex biologics production.

In India, the biopharmaceutical sector is rapidly expanding, fueled by cost-effective manufacturing capabilities and a growing clinical research environment. National initiatives such as "Make in India" and strategic support for biosimilar development have catalyzed infrastructure growth across biotech hubs, creating a strong foundation for increased adoption of mixed mode chromatography technologies.

China is also emerging as a dominant global force in biopharma, with substantial public and private investments directed toward biologics R&D. Government programs like "Healthy China 2030" are accelerating innovation in drug manufacturing, encouraging widespread uptake of modern purification solutions such as mixed mode chromatography resins.

The United Kingdom benefits from a strong academic research base and a vibrant biotech startup ecosystem, both of which contribute to consistent demand. As the country pushes further into personalized medicine and small-batch biologics, the need for high-efficiency, flexible purification methods is steadily growing, bolstering the mixed mode chromatography resins market.

Key Industry Players

Thermo Fisher Scientific
Cytiva (Danaher Corporation)
Merck KGaA (MilliporeSigma)
Agilent Technologies
Bio-Rad Laboratories, Inc.
Tosoh Corporation
GE Healthcare (now part of Cytiva in chromatography)
Purolite Corporation
Avantor (including VWR & Pall acquisitions)
JSR Micro Inc.
Kaneka Corporation
Sepragen Corporation
Repligen Corporation
Bio-Works Technologies

Competitive Landscape

The mixed-mode chromatography resin market is moderately concentrated, with key players such as Merck KGaA, Bio-Rad Laboratories, and Tosoh Corporation holding significant market shares. These companies actively compete through strategies centered on innovation, strategic collaborations, and capacity expansions to meet the rising demand for advanced purification solutions in biopharmaceutical manufacturing.

In 2024, Merck KGaA announced the expansion of its chromatography resin production capabilities. This move aims to support increasing global demand for high-performance resins used in the purification of monoclonal antibodies and other complex biologics, reflecting the growing scale and complexity of biopharma production pipelines.

Also in 2024, Bio-Rad Laboratories introduced a new line of high-performance ion-exchange chromatography resins tailored specifically for the biopharmaceutical industry. These resins are designed to deliver enhanced binding capacity and selectivity, addressing the escalating need for efficient protein purification technologies in biologics development.

Meanwhile, Tosoh Corporation continues to strengthen its position through R&D initiatives and quality-focused manufacturing, supporting global clients across biologics and biosimilar production. Collectively, these advancements highlight the sector's push toward greater efficiency, scalability, and process optimization in bioprocessing.

Browse Full Report: https://www.factmr.com/report/mixed-mode-chromatography-resin-market

Segmentation

By Type:

Ion Exchange-Hydrophobic Type
Hydroxyapatite Type
Others
By Application:

Antibodies Production
Vaccine Production
Non-antibody Proteins
Antibody-drug conjugate
Separation of low molecular weight impurities
By Region:

North America
Latin America
Europe
Asia Pacific
Middle East and Africa (MEA)

Check out More Related Studies Published by Fact.MR:

Genu Recurvatum Market
https://www.factmr.com/report/genu-recurvatum-market
Hemianopsia Market
https://www.factmr.com/report/hemianopsia-market
Chronic Idiopathic Constipation Treatment Market
https://www.factmr.com/report/chronic-idiopathic-constipation-treatment-market
Grand Mal Seizure Treatment Market
https://www.factmr.com/report/grand-mal-seizure-treatment-market

Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

About Fact.MR
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.